AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2025
Aug 13, 2025
30604_dirs_2025-08-12_d4f393f4-bf72-4214-85d0-46a8cf2551af.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-08-08
Reporting Person: HOMCY CHARLES J (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-08-08 | Common Stock | S | 191662 | $45.8703 | Disposed | 1025012 | Direct |
| 2025-08-08 | Common Stock | S | 58338 | $46.6394 | Disposed | 966674 | Direct |
| 2025-08-11 | Common Stock | S | 50000 | $48 | Disposed | 916674 | Direct |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 8, 2025.
F2: Represents the weighted average sale price of the shares sold from $45.395 to $46.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3: Represents the weighted average sale price of the shares sold from $46.40 to $46.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.